Innovo Biopolymers is advancing a broad range of biomedical applications which can be developed or greatly improved by harnessing our novel Polyphosphazene (PPZ) Biopolymer Platform Technology. Our technology has enormous potential to displace established alternatives and create new applications in cancer immunotherapies, vaccines, protein drugs and implantable medical devices.
Innovo Biopolymers, LLC (Rockville, MD) was formed in 2015 to leverage the cutting edge PPZ research in the laboratory of Dr. Alexander Andrianov at the University of Maryland’s Institute of Bioscience and Biotechnology Research (IBBR), in combination with a portfolio of synergistic patents and knowhow acquired by the company from Parallel Solutions Inc. (PSI), a former MIT spinoff. Dr. Andrianov is a recognized world expert with over 70 publications, including “Biomedical Applications of Polyphosphazenes”, a reference textbook in the field. His laboratory maintains an ongoing program developing innovations in chemistry, manufacturing and new applications of PPZ technologies, and undertakes collaborations with many academic, government and industry groups.